Key result
Cilostazol plus aspirin resulted in a higher rate of subacute thrombosis compared to ticlopidine plus aspirin after coronary stenting, with no difference in restenosis.
Why the study?
Does cilostazol plus aspirin improve angiographic or clinical outcomes compared to ticlopidine plus aspirin in patients after coronary stenting?
RCT (n=642)
Open-label
Standard list of random numbers
No
Does cilostazol plus aspirin improve angiographic or clinical outcomes compared to ticlopidine plus aspirin in patients after coronary stenting?
Cilostazol is associated with a significantly higher risk of subacute thrombosis compared to ticlopidine when used as dual antiplatelet therapy after coronary stenting, despite similar angiographic restenosis rates.
Answers are grounded in this paper and cite their sources.
Cilostazol plus aspirin should be avoided post-stenting due to excess thrombosis risk; challenges its use as an alternative to ticlopidine in dual antiplatelet regimens.
BACKGROUND: Cilostazol and ticlopidine are commonly prescribed for prevention of thrombosis after coronary stenting, but few studies have compared them. METHODS AND RESULTS: In the present study 642 patients who underwent stenting were randomized to treatment either with cilostazol + aspirin (C group, 321 patients) or ticlopidine + aspirin (T group, 321 patients). Quantitative coronary angiography (QCA) was performed immediately after stenting and at the 6-month follow-up. Treatment was continued until follow-up angiography. Baseline patient characteristics did not differ significantly. With the exception of a higher rate of stenting in a venous graft in the C group, there were no differences in angiographic characteristics or stent type. Baseline QCA analysis of the reference diameter, minimal lumen diameter (MLD) showed no significant differences. Follow-up QCA analysis of the MLD showed no significant differences. There were also no differences in restenosis or target lesion revascularization rates, or in the incidence of adverse reactions. However, the rate of subacute thrombosis (SAT) was significantly higher in the C group than in the T group (2% vs 0.3%, p=0.02). CONCLUSION: In the present study there was a similar restenosis rate with cilostazol or ticlopidine, but the rate of SAT was significantly higher with cilostazol. There was no significant difference in adverse reactions.
No takes yet. Share an insight, caveat, or question.
Takeyasu et al. (2005) conducted an RCT in Ischemic heart disease requiring coronary stenting (n=642). Cilostazol + aspirin vs. Ticlopidine 200 mg/day + aspirin 81-200 mg/day was evaluated on Subacute thrombosis (SAT) (p=0.02). Cilostazol plus aspirin resulted in a higher rate of subacute thrombosis compared to ticlopidine plus aspirin after coronary stenting, with no difference in restenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: